Ultragenyx Pharmaceutical (RARE) Liabilities and Shareholders Equity (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.21% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 billion (down 10.83% YoY) and the FY2025 annual result came in at $1.5 billion, up 1.93% from the prior year.
• Liabilities and Shareholders Equity fell to $1.3 billion in Q1 2026 per RARE's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q3 2022 and bottomed at $1.2 billion in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.4 billion (2023), against an average of $1.4 billion.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity decreased 23.5%; it then grew 24.25% in 2024.
• Tracing RARE's Liabilities and Shareholders Equity over 5 years: stood at $1.5 billion in 2022, then dropped by 3.52% to $1.5 billion in 2023, then gained by 0.8% to $1.5 billion in 2024, then grew by 1.93% to $1.5 billion in 2025, then decreased by 15.4% to $1.3 billion in 2026.
• Per Business Quant, the three latest RARE Liabilities and Shareholders Equity figures stand at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.2 billion (Q3 2025).

Peer Comparison